• 03.01.18

    Deceptive Pricing Suit Survives Dismissal Motion

    A deceptive pricing suit against Hobby Lobby will move forward after a California federal court judge denied the company’s motion to dismiss.

  • 02.22.18

    Fake Social Followers Yield Real Legal Concerns

    Lawmakers asked for an inquiry into a company that allegedly sells fake social media followers after news broke that celebrities and public figures were making purchases to bulk up their followings.

  • 02.22.18

    Ad Agency Pays FTC $2M in Record Deal

    In the largest payment ever made by an advertising agency in a Federal Trade Commission (FTC) action, Marketing Architects agreed to pay $2 million over allegedly deceptive radio ads for weight loss products.

  • 02.22.18

    Dodge Fumbles Super Bowl Ad

    Another year, another Super Bowl ad controversy.

  • 02.22.18

    COPPA, FTC Act Violations for Talent Agency

    A talent agency was the target of the 30th Children’s Online Privacy Protection Act (COPPA) action by the Federal Trade Commission (FTC) based on allegations it failed to obtain parental consent before collecting personal information from child performers and neglected to inform their parents ...

  • 02.15.18

    IAB Seeks to Influence Marketers, Publishers With Influencer Guidance

    Need help with influencer marketing? The Interactive Advertising Bureau has published a new guide that publishers and marketers can use to maximize their influencer marketing programs.

  • 02.15.18

    The FTC’s Clean Slate

    For the Federal Trade Commission (FTC), 2018 looks to be a year of transition, with President Donald J. Trump officially submitting four commissioner nominations for Senate approval.

  • 02.15.18

    Question Mark Leaves Court Questioning Defamation Claim

    Demonstrating the power of punctuation, actor James Woods dodged a Twitter defamation suit after a federal court judge found that his use of a question mark meant his tweet was not a false statement of fact and merely invited the reader to reach his or her own conclusion.

  • 02.15.18

    NAD: Allergy Medication Too Smart for Its Own Good

    Claims touting an allergy medication as “smart” or “wise” conferred a clinically meaningful benefit as compared to a competitor’s product and should be discontinued, the National Advertising Division (NAD) recently recommended.

  • 02.08.18

    FTC Keeps Its Hat On Over ‘Made in USA’ Claims

    Tipping its hat to the Enforcement Policy Statement on U.S. Origin Claims, the Federal Trade Commission (FTC) filed suit against Bollman Hat Co. and a subsidiary for deceiving consumers with “Made in USA” claims for its hats and third-party products. 

manatt-black

ATTORNEY ADVERTISING

pursuant to New York DR 2-101(f)

© 2024 Manatt, Phelps & Phillips, LLP.

All rights reserved